Catalyst Pharmaceuticals reports Q3 EPS 68c, consensus 54c

Reports Q3 revenue $148.39M, consensus $136.8M. “Throughout 2025, we have continued to execute on our commercial growth initiatives to drive adoption of FIRDAPSE(R) and AGAMREE(R), resulting in another quarter of strong financial performance,” stated Rich Daly, President and CEO of Catalyst. “Our third quarter performance was driven by our best-in-class product portfolio and our focus on creating value for patients taking FIRDAPSE and AGAMREE who participate in our Catalyst Pathways(R) program. We believe that this program both enhances access as well as contributes to medication compliance and persistence.”